Outcomes of intermediate or high-risk CMML patients treated with HMAs combined with Venetoclax: a single center experience.

Chronic myelomonocytic leukemia (CMML) treatment remains a pressing clinical challenge. We conducted a retrospective analysis on 52 CMML cases, exploring the effectiveness of combining venetoclax(Vene) with Hypomethylating agents (HMAs). The study's findings show promise: the HMAs plus Vene group (n=13, 53.8%) demonstrated superior overall response rates compared to the HMA mono group (n=19, 31.6%) and HMA plus arsenic trioxide (ATO) group (n=9, 22.2%) by the 2nd cycle, and notably higher response rates (53.8% vs. 15.7%, P = 0.04) compared to the HMA mono group after four cycles. Over a median follow-up of 14.7 months, the HMAs plus Vene group exhibited significantly lower cumulative mortality (23.1%) compared to the other two groups (P = 0.003 and P = 0.008, respectively). Furthermore, this group displayed extended overall survival (OS) compared to the others. The study also delved into the molecular mechanisms, revealing significant BCL2 mRNA overexpression in CMML patients. These findings suggest the potential for HMAs combined with Vene therapy in CMML but emphasize the necessity for further prospective studies to determine its precise role in managing CMML.